#pfizer Instagram Story & Photos & Videos

pfizer - 34.4k posts

Advertisements

  • New entry in showroom: i ladri!
    Ringrazio la #poliziadistato e #pfizer produttrice di un gradevole farmaco: Xanax. 不不不
  • New entry in showroom: i ladri!
Ringrazio la #poliziadistato e #pfizer produttrice di un gradevole farmaco: Xanax. 不不不
  •  1  0 7 hours ago
  • Would yall just look at this chunky little baby? I still cant believe I gave birth to a child who was almost 10 pounds! Hes a little more average in size now, but as a little infant I could not get enough of his squish! I love going to his pediatrician and seeing how much hes grown and how hes developing.

    Regular baby checkups are incredibly important to tracking a babys development, and may alert parents to potential issues early.

    For more information about baby checkups, check out @PfizerInc s campaign. Link in bio!

    #sponsored #Pfizer #babiesofinstagram
  • Would yall just look at this chunky little baby? I still cant believe I gave birth to a child who was almost 10 pounds! Hes a little more average in size now, but as a little infant I could not get enough of his squish! I love going to his pediatrician and seeing how much hes grown and how hes developing.

Regular baby checkups are incredibly important to tracking a babys development, and may alert parents to potential issues early.

For more information about baby checkups, check out @PfizerIncs campaign. Link in bio!

#sponsored #Pfizer #babiesofinstagram
  •  133  11 8 hours ago

Advertisements

  • The U.S. FDA this week released two new draft Q&A guidance documents on biosimilar development and the deemed to be a license provision of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), as well as two final guidance documents on the same topics and one proposed rule amending the definition of a biological product. The efforts are part of the FDA's decade-long work to begin, starting in March 2020, transitioning the approved marketing applications for a subset of biological products, such as insulin and human growth hormone - which were previously approved as drugs under section 505 of the FD&C Act - to be deemed to be biologics licenses.
  • The U.S. FDA this week released two new draft Q&A guidance documents on biosimilar development and the deemed to be a license provision of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), as well as two final guidance documents on the same topics and one proposed rule amending the definition of a biological product. The efforts are part of the FDA's decade-long work to begin, starting in March 2020, transitioning the approved marketing applications for a subset of biological products, such as insulin and human growth hormone - which were previously approved as drugs under section 505 of the FD&C Act - to be deemed to be biologics licenses.
  •  16  2 9 hours ago
  • WuXi AppTec has announced the expansion of its facilities in San Diego, California. The newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.
  • WuXi AppTec has announced the expansion of its facilities in San Diego, California. The newly expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including phase I GMP manufacturing. The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries. WuXi will also add extensively from the local talent base, further contributing to regional economic growth.
  •  7  1 9 hours ago
  • Pfizer will add about 100 new jobs in oncology research and development at its La Jolla, California site, as its Cancer Immunology Discovery unit relocates out of South San Francisco and the company eliminates 100 roles there. A recent filing with the state of California disclosed the 100 expected layoffs in South San Francisco, set to take effect on February 18th, 2019. The shift will make the La Jolla campus one of the "largest pharmaceutical research centers" in the San Diego area, according to a Pfizer spokesperson.
  • Pfizer will add about 100 new jobs in oncology research and development at its La Jolla, California site, as its Cancer Immunology Discovery unit relocates out of South San Francisco and the company eliminates 100 roles there. A recent filing with the state of California disclosed the 100 expected layoffs in South San Francisco, set to take effect on February 18th, 2019. The shift will make the La Jolla campus one of the "largest pharmaceutical research centers" in the San Diego area, according to a Pfizer spokesperson.
  •  7  2 9 hours ago

Advertisements

Advertisements

  • Sem legendas #pfizer
  • Sem legendas #pfizer
  •  19  0 12 hours ago
  • Decorreu hoje entre as 11h e as 15h, o Mercado de Natal Solid獺rio na Galeria Comercial do Lagoas Park. O mercado decorre nos dias 12 e 13 de dezembro.
    A@associacaocais esteve hoje presente com aPfizer e amanh瓊 tamb矇m marcar獺 presen癟a.

    Visite-nos amanh瓊, no nosso espa癟o, entre as 15h e as 11h, e encontre a mais recente edi癟瓊o do Livro de Natal da CAIS - O cora癟瓊o do Nicolau - bem como, as edi癟繭es anteriores.

    #AssociacaoCAIS #TodosContam #LagoasPark #Pfizer
  • Decorreu hoje entre as 11h e as 15h, o Mercado de Natal Solid獺rio na Galeria Comercial do Lagoas Park. O mercado decorre nos dias 12 e 13 de dezembro. 
A@associacaocaisesteve hoje presente com aPfizer e amanh瓊 tamb矇m marcar獺 presen癟a.

Visite-nos amanh瓊, no nosso espa癟o, entre as 15h e as 11h, e encontre a mais recente edi癟瓊o do Livro de Natal da CAIS - O cora癟瓊o do Nicolau - bem como, as edi癟繭es anteriores.

#AssociacaoCAIS#TodosContam#LagoasPark#Pfizer
  •  19  0 19 hours ago

Advertisements

  • Did you know that in early 1996, Nigeria was hit by the one of the worst meningitis epidemics in history with over 11,000 causalities? About the same time, in order to secure certification from the Food and Drug Administration (FDA) in the US, a pharmaceutical company needed to conduct a clinical trial and they had hoped that Africa could be used to furnish proof that the new drug was safe for children. The outbreak of meningitis in Nigeria was the opening the company needed. That company is Pfizer pharmaceutical.

    In the spring of 1996, the company offered to help the government deal with the epidemic and in March, a medical team arrived in Nigeria. Upon their arrival in Kano, the Americans revealed that they had been sent to carry out medical tests and the physicians selected 200 sick children for the study which took place at the Infectious Diseases Hospital (IDH). Their criteria were that the patients had to be between three months old and 18 years old, HIV negative and not malnourished. About 11 persons died while almost 200 persons are believed to have suffered various physical deformities as a result of the trials. The untested drug that was administered to those children is Trovan (trovafloxacin). #nigeria #nigerianahthemovie #pfizer #jointheconversation
  • Did you know that in early 1996, Nigeria was hit by the one of the worst meningitis epidemics in history with over 11,000 causalities? About the same time, in order to secure certification from the Food and Drug Administration (FDA) in the US, a pharmaceutical company needed to conduct a clinical trial and they had hoped that Africa could be used to furnish proof that the new drug was safe for children. The outbreak of meningitis in Nigeria was the opening the company needed. That company is Pfizer pharmaceutical.

In the spring of 1996, the company offered to help the government deal with the epidemic and in March, a medical team arrived in Nigeria.  Upon their arrival in Kano, the Americans revealed that they had been sent to carry out medical tests and the physicians selected 200 sick children for the study which took place at the Infectious Diseases Hospital (IDH). Their criteria were that the patients had to be between three months old and 18 years old, HIV negative and not malnourished. About 11 persons died while almost 200 persons are believed to have suffered various physical deformities as a result of the trials. The untested drug that was administered to those children is Trovan (trovafloxacin). #nigeria #nigerianahthemovie #pfizer #jointheconversation
  •  68  4 22 hours ago
  • Boehringer Ingelheim told unions this week that it plans to cut some 300 jobs in France as part of efforts to reorganize activities around its hub in Lyon following an asset swap with Sanofi.

    Boehringer Ingelheim's chairman for France, Jean Scheftsik de Szolnok, has said that the company was planning to cut up to 327 jobs out of a 2,800 workforce in France.

    However, it will also create 32 new positions. He said the plan was to offer voluntary departure packages to avoid forced exits, but added that it was too early to give a timeframe. Alert readers will recall that Boehringer agreed in January of last year to trade its consumer health division in exchange for France's Sanofi animal health arm Merial in a $20 billion transaction.
  • Boehringer Ingelheim told unions this week that it plans to cut some 300 jobs in France as part of efforts to reorganize activities around its hub in Lyon following an asset swap with Sanofi.

Boehringer Ingelheim's chairman for France, Jean Scheftsik de Szolnok, has said that the company was planning to cut up to 327 jobs out of a 2,800 workforce in France.

However, it will also create 32 new positions. He said the plan was to offer voluntary departure packages to avoid forced exits, but added that it was too early to give a timeframe. Alert readers will recall that Boehringer agreed in January of last year to trade its consumer health division in exchange for France's Sanofi animal health arm Merial in a $20 billion transaction.
  •  28  2 12 December, 2018

Advertisements

  • Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells.
    The report that will be appearing in the journal Immunity and has been published online suggests potential ways of improving the efficacy and broadening the application of anti-PD-1 therapies. "Although anti-PD-1 checkpoint immunotherapy has proven incredibly useful against some cancers, we still know relatively few specifics on how the treatment works," says Mikael Pittet, Ph.D., of the MGH Center for Systems Biology (CSB), senior author of the Immunity paper. "Here we show that a more complex interaction between cytotoxic T cells and intratumor dendritic cells is needed to release the brakes on T cell immunity that normally prevent the immune system from responding to cancers." found that anti-PD-1 drugs induced CD8+ T cells to produce interferon-gamma (INF-帠), which is one of the most important cytokines for an anti-cancer immune response. What was less expected is that neighboring dendritic cells also started to produce copious amounts of IL-12 in response to anti-PD-1 treatment." The researchers further found that IFN-帠 produced by the T cells induces dendritic cells to produce IL-12, which acts as a potent and necessary activating signal that enables CD8+ T cells to attack the tumor. For more info 8). DOI: 10.1016/j.immuni.2018.09.024
    #immunotherapy #pdl1 #interferon #dendriticcell #interleukin #immunology #immunesystem #clinicaltrials For more information about MSL/Medical Affairs jobs and posts, follow our company LinkedIn page at http://tiny.cc/LIcompany

    #msl #medicalscience #immunotherapy #medicalscienceliaison #medicalaffairs #clinicalscience #pharmaceuticals #pharmaceuticalindustry #Astrazeneca #Takeda #Novartis #Amgen #Genentech #Pfizer #roche #Bayer
  • Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells. 
The report that will be appearing in the journal Immunity and has been published online suggests potential ways of improving the efficacy and broadening the application of anti-PD-1 therapies. "Although anti-PD-1 checkpoint immunotherapy has proven incredibly useful against some cancers, we still know relatively few specifics on how the treatment works," says Mikael Pittet, Ph.D., of the MGH Center for Systems Biology (CSB), senior author of the Immunity paper. "Here we show that a more complex interaction between cytotoxic T cells and intratumor dendritic cells is needed to release the brakes on T cell immunity that normally prevent the immune system from responding to cancers." found that anti-PD-1 drugs induced CD8+ T cells to produce interferon-gamma (INF-帠), which is one of the most important cytokines for an anti-cancer immune response. What was less expected is that neighboring dendritic cells also started to produce copious amounts of IL-12 in response to anti-PD-1 treatment." The researchers further found that IFN-帠 produced by the T cells induces dendritic cells to produce IL-12, which acts as a potent and necessary activating signal that enables CD8+ T cells to attack the tumor. For more info 8). DOI: 10.1016/j.immuni.2018.09.024 
#immunotherapy #pdl1 #interferon #dendriticcell #interleukin #immunology #immunesystem #clinicaltrials For more information about MSL/Medical Affairs jobs and posts, follow our company  LinkedIn page at http://tiny.cc/LIcompany

#msl #medicalscience #immunotherapy #medicalscienceliaison #medicalaffairs #clinicalscience #pharmaceuticals #pharmaceuticalindustry #Astrazeneca #Takeda #Novartis #Amgen #Genentech #Pfizer #roche #Bayer
  •  17  0 12 December, 2018
  • #Pfizer lanz籀 su nuevo anticonceptivo Sayana Press con una entretenida presentaci籀n de realidad virtual!
    Bienvenida la revoluci籀n de la anticoncepci籀n! @ Sky Costanera
  • #Pfizer lanz籀 su nuevo anticonceptivo Sayana Press con una entretenida presentaci籀n de realidad virtual!
Bienvenida la revoluci籀n de la anticoncepci籀n!  @ Sky Costanera
  •  0  0 12 December, 2018
  • IPhO held their last meeting of the semester with #guestspeaker Dr. Richa Shah, Medical Director, Oncology, US Medical Affairs at #pfizer who hasnt questions post #midyear
  • IPhO held their last meeting of the semester with #guestspeaker Dr. Richa Shah, Medical Director, Oncology, US Medical Affairs at #pfizer who hasnt questions post #midyear
  •  13  1 12 December, 2018
  • Gilead has announced that longtime Roche veteran Daniel O'Day will assume the role of Chairman and CEO at Gilead beginning on March 1st, 2019. This comes as current Gilead CEO, John Milligan and Chairman John Martin, leave the company at the end of this year. In related news, Roche has announced the appointment of Bill Anderson, currently head of its Genentech unit, to lead its Pharma division. These changes come at a critical time for both company's as they look to navigate a rapidly evolving biopharma market full of challenges and opportunities.
  • Gilead has announced that longtime Roche veteran Daniel O'Day will assume the role of Chairman and CEO at Gilead beginning on March 1st, 2019. This comes as current Gilead CEO, John Milligan and Chairman John Martin, leave the company at the end of this year. In related news, Roche has announced the appointment of Bill Anderson, currently head of its Genentech unit, to lead its Pharma division. These changes come at a critical time for both company's as they look to navigate a rapidly evolving biopharma market full of challenges and opportunities.
  •  24  4 11 December, 2018
  • The Swiss contracting giant Lonza is partnering with GE Healthcare to build a manufacturing facility in China for biologic drugs, the contract development and manufacturing organization said Monday. The plant will be roughly 180,000 square feet and employ 160 workers. Lonza expects to be manufacturing out of the site by 2020. The facility, which will focus on antibodies, will be in Guangzhou, a port city northwest of Hong Kong in southern China. The agreement falls within a broader deal GE Healthcare has with the city's economic development zone, called the Guangzhou Development District.
  • The Swiss contracting giant Lonza is partnering with GE Healthcare to build a manufacturing facility in China for biologic drugs, the contract development and manufacturing organization said Monday. The plant will be roughly 180,000 square feet and employ 160 workers. Lonza expects to be manufacturing out of the site by 2020. The facility, which will focus on antibodies, will be in Guangzhou, a port city northwest of Hong Kong in southern China. The agreement falls within a broader deal GE Healthcare has with the city's economic development zone, called the Guangzhou Development District.
  •  21  2 11 December, 2018